ELAC2

Across TCGA pan-cancer cohorts, ELAC2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ELAC2 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ELAC2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ELAC2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

COAD, CCRCC, and LSCC are the cancer types where ELAC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	0.909	1.000	.010	48	view →
CCRCC	DFS	Tertile	All	1.000	0.480	.004	35	view →
LSCC	OS	Quartile	II,III,IV	0.927	0.517	.005	8	view →
UCEC	DFS	Tertile	All	0.876	0.985	.031	6	view →
PDAC	DFS	Tertile	IV	0.752	0.199	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ELAC2–COAD (DFS)

Open the COAD breakdown →